A Phase II, Single-Arm Open-Label Study Of The Combination Of Atezolizumab And Bevacizumab In Rare Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Mesothelioma; Pharyngeal neoplasms; Soft tissue sarcoma; Solid tumours
- Focus Therapeutic Use
- 10 Mar 2017 New trial record
- 08 Mar 2017 Planned End Date changed from 1 May 2021 to 1 Mar 2021.
- 08 Mar 2017 Planned primary completion date changed from 1 May 2021 to 1 Mar 2021.